Chemed Corporation entered into an amended and restated credit agreement on April 10, 2026, and announced the transaction on April 13, 2026. The agreement provides a five‑year, $450 million revolving credit facility, including a $100 million sublimit for letters of credit, a floating SOFR‑based interest rate, and an expansion feature that would allow the company to increase the revolver by an additional $250 million if needed.
JPMorgan Chase Bank, N.A. serves as the administrative agent, joint lead arranger, and joint bookrunner. Bank of America, N.A., PNC N.A., and U.S. Bank N.A. act as co‑documentation agents. The facility is designed to support Chemed’s two operating segments—VITAS Healthcare and Roto‑Rooter—and to provide working‑capital flexibility for both businesses.
The announcement follows a fourth‑quarter 2025 earnings miss, with EPS of $6.42 versus $7.07 expected and revenue of $639.34 million versus $658.97 million expected. The miss, coupled with an RBC Capital downgrade over margin uncertainties in Roto‑Rooter, prompted management to secure additional liquidity. The new credit line, while maintaining a very low debt‑to‑equity ratio of 0.15, reinforces Chemed’s conservative financial strategy and positions the company to fund potential acquisitions, capital expenditures, or share‑repurchase programs.
Chemed’s prior credit facility, entered in June 2022, was a $550 million agreement that included a $100 million term loan and a $450 million revolving credit facility. The current amendment keeps the same revolving amount but updates terms and expands the credit limit, reflecting the company’s ongoing need for flexible financing amid a competitive market for service‑based businesses.
The facility’s SOFR‑based interest rate aligns with industry benchmarks, and the expansion feature allows Chemed to increase the revolver by $250 million if needed. By securing this line, Chemed signals confidence in its ability to manage cash flow, support its hospice and plumbing operations, and maintain a strong balance sheet even as it pursues growth opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.